Journal of Clinical Oncology, Vol 16, 664-669, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study

KA Margolin, PY Liu, LE Flaherty, JA Sosman, MJ Walker, JW Smith 3rd, WS Fletcher, GR Weiss, JM Unger and VK Sondak
City of Hope National Medical Center, Duarte, CA, USA.

PURPOSE: The combination of carmustine (BCNU), dacarbazine (DTIC), cisplatin (DDP), and tamoxifen (Tam) has been reported in small series to provide a response rate of 50%, but with significant myelosuppression and risk of thromboembolic complications. We performed this phase II study to assess the antitumor activity and important toxicities of this combination in the cooperative group setting. PATIENTS AND METHODS: Seventy-nine eligible patients were treated with BCNU 150 mg/m2/d, every 6 weeks, DTIC 220 mg/m2/d on days 1 to 3 every 3 weeks, DDP 25 mg/m2/d on days 1 to 3 every 3 weeks, and Tam 20 mg orally daily throughout treatment. Treatment cycles were repeated every 6 weeks in responding or stable patients for a maximum duration of 1 year. RESULTS: Twelve objective responses were achieved (response rate 15%, 95% confidence interval 8%-25%). Five responses were complete (CR) and seven were partial (PR). The median response duration was 8+ (range, 4-19+) months, (16+ [4-19+] for CR and 8+ [4-11] for PR), and the median survival of the entire group was 9 months. The toxicities were predominantly neutropenia and thrombocytopenia. Four patients developed thromboembolic events. Two patients died while on protocol therapy, one with complications of neutropenia, and the other with disease progression. CONCLUSION: The activity of this regimen is in the range reported for single agents or DTIC plus DDP, and the addition of BCNU and Tam appears to increase toxicity. We do not recommend this combination for routine treatment of advanced melanoma or as the control arm in randomized studies of combination therapy.

This article has been cited by other articles:

				E. L. Korn, P.-Y. Liu, S. J. Lee, J.-A. W. Chapman, D. Niedzwiecki, V. J. Suman, J. Moon, V. K. Sondak, M. B. Atkins, E. A. Eisenhauer, et al. Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials J. Clin. Oncol., February 1, 2008; 26(4): 527 - 534. [Abstract] [Full Text] [PDF]

				K. A. DiVito, A. J. Berger, R. L. Camp, M. Dolled-Filhart, D. L. Rimm, and H. M. Kluger Automated Quantitative Analysis of Tissue Microarrays Reveals an Association between High Bcl-2 Expression and Improved Outcome in Melanoma Cancer Res., December 1, 2004; 64(23): 8773 - 8777. [Abstract] [Full Text] [PDF]

				L. E. Flaherty, M. Atkins, J. Sosman, G. Weiss, J. I. Clark, K. Margolin, J. Dutcher, M. S. Gordon, M. Lotze, J. Mier, et al. Outpatient Biochemotherapy With Interleukin-2 and Interferon Alfa-2b in Patients With Metastatic Malignant Melanoma: Results of Two Phase II Cytokine Working Group Trials J. Clin. Oncol., July 1, 2001; 19(13): 3194 - 3202. [Abstract] [Full Text] [PDF]

				P. B. Chapman, L. H. Einhorn, M. L. Meyers, S. Saxman, A. N. Destro, K. S. Panageas, C. B. Begg, S. S. Agarwala, L. M. Schuchter, M. S. Ernstoff, et al. Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma J. Clin. Oncol., September 1, 1999; 17(9): 2745 - 2745. [Abstract] [Full Text] [PDF]

				S. J. O'Day, G. Gammon, P. D. Boasberg, M. A. Martin, T. S. Kristedja, M. Guo, S. Stern, S. Edwards, P. Fournier, M. Weisberg, et al. Advantages of Concurrent Biochemotherapy Modified by Decrescendo Interleukin-2, Granulocyte Colony-Stimulating Factor, and Tamoxifen for Patients With Metastatic Melanoma J. Clin. Oncol., September 1, 1999; 17(9): 2752 - 2752. [Abstract] [Full Text] [PDF]

				E. T. Creagan, V. J. Suman, R. J. Dalton, H. C. Pitot, H. J. Long, M. H. Veeder, A. M. Vukov, K. M. Rowland, J. E. Krook, and J. C. Michalak Phase III Clinical Trial of the Combination of Cisplatin, Dacarbazine, and Carmustine With or Without Tamoxifen in Patients With Advanced Malignant Melanoma J. Clin. Oncol., June 1, 1999; 17(6): 1884 - 1884. [Abstract] [Full Text] [PDF]

				S. A. Rosenberg, J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, C. A. Seipp, J. H. Einhorn, D. E. White, and S. M. Steinberg Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin-2 and Interferon Alfa-2b J. Clin. Oncol., March 1, 1999; 17(3): 968 - 968. [Abstract] [Full Text] [PDF]